Skip to main
SOLV
SOLV logo

Solventum Corporation (SOLV) Stock Forecast & Price Target

Solventum Corporation (SOLV) Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 0%
Buy 25%
Hold 63%
Sell 0%
Strong Sell 13%

Bulls say

Solventum Corp is positioned for robust growth due to its strategic focus on market development and penetration, particularly within its core MedSurg segment that addresses critical healing needs. The company's emphasis on accelerating global adoption of antimicrobial solutions and elevating standards of care suggests a commitment to innovation and improved patient outcomes, which could enhance its competitive positioning. Additionally, the anticipated growth in Revenue Cycle Management, driven by expanded capabilities and international expansion, further underlines the company's potential to capitalize on emerging market opportunities.

Bears say

Solventum Corp has faced a persistent decline in volume growth, with the company experiencing seven consecutive quarters of negative volumes prior to its spin-off. Additionally, projections indicate a potential gross margin decline of approximately 40 basis points in 2026, attributed to the anticipated impact of tariffs. These factors contribute to a negative outlook on the company’s financial performance and overall market positioning.

Solventum Corporation (SOLV) has been analyzed by 8 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 25% recommend Buy, 63% suggest Holding, 0% advise Selling, and 13% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solventum Corporation and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solventum Corporation (SOLV) Forecast

Analysts have given Solventum Corporation (SOLV) a Hold based on their latest research and market trends.

According to 8 analysts, Solventum Corporation (SOLV) has a Hold consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $84.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $84.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solventum Corporation (SOLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.